Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.19 USD | -2.31% | -0.42% | -41.26% |
Apr. 01 | Sector Update: Health Care Stocks Slide Late Afternoon | MT |
Apr. 01 | Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans | MT |
Financials (USD)
Sales 2021 | 1.42 | Sales 2022 | 0.7 | Capitalization | 103M |
---|---|---|---|---|---|
Net income 2021 | -63M | Net income 2022 | -58M | EV / Sales 2021 | 297,232,229 x |
Net cash position 2021 | 17.36M | Net Debt 2022 | 14.82M | EV / Sales 2022 | 168,485,877 x |
P/E ratio 2021 |
-6.51
x | P/E ratio 2022 |
-1.61
x | Employees | 61 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 29.62% |
Latest transcript on Pulse Biosciences, Inc.
1 day | -2.31% | ||
1 week | -0.42% | ||
Current month | -17.45% | ||
1 month | -22.85% | ||
3 months | -13.16% | ||
6 months | +81.11% | ||
Current year | -41.26% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Danahy
CEO | Chief Executive Officer | 54 | 22-02-13 |
Chief Tech/Sci/R&D Officer | - | 23-05-02 | |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Duggan
CHM | Chairman | 79 | 17-11-01 |
Director/Board Member | 46 | 17-11-01 | |
Darrin Uecker
CTO | Chief Tech/Sci/R&D Officer | 59 | 15-09-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.36% | 4 M€ | -5.15% | - | |
0.00% | 34 M€ | +1.25% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 7.36 | -1.47% | 147,946 |
24-04-17 | 7.47 | -3.98% | 149,671 |
24-04-16 | 7.78 | -0.51% | 113,563 |
24-04-15 | 7.82 | +8.31% | 328,356 |
24-04-12 | 7.22 | -0.55% | 133,963 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-41.26% | 406M | |
+2.64% | 207B | |
+1.80% | 175B | |
+8.59% | 132B | |
+16.47% | 99.1B | |
-3.42% | 60.89B | |
+12.71% | 52.04B | |
-6.61% | 45.48B | |
-4.53% | 38.81B | |
+9.27% | 38.77B |
- Stock Market
- Equities
- PLSE Stock